Higher TMB significantly predicts a desirable result of PD-1/PD-L1 blockade both in NSCLC and SCLC, implying that comprehensive genomic profiling analysis might lead to patient benefit (Hellmann et al., 2018; Reck et al., 2019; Ricciuti et al., 2019). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.